دورية أكاديمية
Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors.
| العنوان: | Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors. |
|---|---|
| المؤلفون: | Kelly D; Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G1Z5, Canada., Rose AAN; Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G1Z5, Canada.; Department of Oncology, McGill University, Montreal, QC H3A1G5, Canada.; Segal Cancer Centre & Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC H3T1E2, Canada., Muniz TP; Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G1Z5, Canada., Hogg D; Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G1Z5, Canada., Butler MO; Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G1Z5, Canada.; Princess Margaret Cancer Center, Tumor Immunotherapy Program, Toronto, ON M5G1Z5, Canada., Saibil SD; Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G1Z5, Canada.; Princess Margaret Cancer Center, Tumor Immunotherapy Program, Toronto, ON M5G1Z5, Canada., King I; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5G1Z5, Canada.; Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1Z5, Canada., Kamil ZS; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5G1Z5, Canada.; Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1Z5, Canada., Ghazarian D; Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5G1Z5, Canada.; Princess Margaret Cancer Center, University Health Network, Toronto, ON M5G1Z5, Canada., Ross K; Princess Margaret Cancer Center, Tumor Immunotherapy Program, Toronto, ON M5G1Z5, Canada., Iafolla M; Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G1Z5, Canada.; Princess Margaret Cancer Center, Tumor Immunotherapy Program, Toronto, ON M5G1Z5, Canada., Araujo DV; Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G1Z5, Canada.; Department of Medical Oncology, Hospital de Base, Sao Jose do Rio Preto 15090-000, SP, Brazil., Waldron J; Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON M5G1Z5, Canada., Laperriere N; Princess Margaret Cancer Centre, Department of Radiation Oncology, University of Toronto, Toronto, ON M5G1Z5, Canada., Krema H; Princess Margaret Cancer Centre, Ocular Oncology Service Krembil Research Institute, University Health Network, Toronto, ON M5G2C1, Canada., Spreafico A; Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, University Health Network, Toronto, ON M5G1Z5, Canada.; Princess Margaret Cancer Center, Tumor Immunotherapy Program, Toronto, ON M5G1Z5, Canada. |
| المصدر: | Cancers [Cancers (Basel)] 2021 Jul 20; Vol. 13 (14). Date of Electronic Publication: 2021 Jul 20. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel, Switzerland : MDPI |
| مستخلص: | Metastatic uveal melanoma (mUM) is a rare disease. There are limited data on prognostic clinical factors for overall survival (OS) in patients with mUM treated with immune checkpoint inhibitors (ICI). Retrospective and non-randomized prospective studies have reported response rates of 0-17% for anti-PD1/L1 ± anti-CTLA4 ICI in mUM, indicating a potential benefit only in a subset of patients. This study evaluates the characteristics associated with ICI benefit in patients with mUM. We performed a single-center retrospective cohort study of patients with mUM who received anti-PD1/L1 ± anti-CTLA4 ICI between 2014-2019. Clinical and genomic characteristics were collected from a chart review. Treatment response and clinical progression were determined by physician assessment. Multivariable Cox regression models and Kaplan-Meier log-rank tests were used to assess differences in clinical progression-free survival (cPFS) and OS between groups and identify clinical variables associated with ICI outcomes. We identified 71 mUM patients who received 75 lines of ICI therapy. Of these, 54 received anti-PD1/L1 alone, and 21 received anti-PD1/L1 + anti-CTLA4. Patient characteristics were: 53% female, 48% were 65 or older, 72% received one or fewer lines of prior therapy. Within our cohort, 53% of patients had developed metastatic disease <2 years after their initial diagnosis. Bone metastases were present in 12% of patients. The median cPFS was 2.7 months, and the median OS was 10.0 months. In multivariable analyses for both cPFS and OS, the following variables were associated with a good prognosis: ≥2 years from the initial diagnosis to metastatic disease ( n = 25), LDH < 1.5 × ULN ( n = 45), and absence of bone metastases ( n = 66). We developed a Metastatic Uveal Melanoma Prognostic Score (MUMPS). Patients were divided into 3 MUMPS groups based on the number of the above-mentioned prognostic variables: Poor prognosis (0-1), Intermediate prognosis (2) and Good prognosis (3). Good prognosis patients experienced longer cPFS (6.0 months) and OS (34.5 months) than patients with intermediate (2.3 months cPFS, 9.4 months OS) and poor prognosis disease (1.8 months cPFS, 3.9 months OS); p < 0.0001. We developed MUMPS-a prognostic score based on retrospective data that is comprised of 3 readily available clinical variables (time to metastatic diagnosis, presence of bone metastases, and LDH). This MUMPS score has a potential prognostic value. Further validation in independent datasets is warranted to determine the role of this MUMPS score in selecting ICI treatment management for mUM. |
| References: | J Immunother Cancer. 2020 Dec;8(2):. (PMID: 33262254) Melanoma Res. 2021 Feb 1;31(1):67-75. (PMID: 33234846) Cancer. 2016 Nov 15;122(21):3344-3353. (PMID: 27533448) Semin Oncol. 2010 Apr;37(2):127-38. (PMID: 20494705) Eur Urol. 2014 Mar;65(3):577-84. (PMID: 23962746) JCO Precis Oncol. 2017 Jul;2017:. (PMID: 28890946) J Clin Oncol. 2009 Dec 1;27(34):5794-9. (PMID: 19826129) Clin Cancer Res. 2020 Nov 15;26(22):5869-5878. (PMID: 32816891) J Immunother Cancer. 2018 Feb 12;6(1):13. (PMID: 29433557) J Clin Oncol. 2021 Feb 20;39(6):599-607. (PMID: 33125309) Clin Cancer Res. 2020 Oct 1;26(19):5086-5091. (PMID: 32605909) Melanoma Res. 2018 Dec;28(6):571-577. (PMID: 30067547) J Pathol. 2020 Apr;250(4):420-439. (PMID: 31960425) Arch Ophthalmol. 2005 Dec;123(12):1639-43. (PMID: 16344433) Sci Rep. 2020 Sep 3;10(1):14607. (PMID: 32884119) J Natl Compr Canc Netw. 2020 Feb;18(2):120-131. (PMID: 32023525) Eur J Cancer. 2017 Sep;82:56-65. (PMID: 28648699) Cancer. 2020 Jan 1;126(1):86-97. (PMID: 31584722) Eur Urol. 2020 Feb;77(2):269-276. (PMID: 31699525) J Clin Oncol. 2021 Feb 20;39(6):586-598. (PMID: 33417511) Curr Oncol. 2020 Aug;27(4):204-214. (PMID: 32905202) Ocul Oncol Pathol. 2017 Nov;3(4):301-303. (PMID: 29344485) Clin Cancer Res. 2019 Sep 1;25(17):5191-5201. (PMID: 30923036) Cancer Treat Rev. 2020 Nov;90:102091. (PMID: 32877777) Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3048-55. (PMID: 19182252) N Engl J Med. 2018 Apr 05;378(14):1277-1290. (PMID: 29562145) Laryngoscope. 2021 Jun;131(6):E1838-E1846. (PMID: 33098338) Cancer Med. 2017 Jul;6(7):1581-1586. (PMID: 28639409) Cardiovasc Intervent Radiol. 2013 Feb;36(1):158-65. (PMID: 22526099) J Clin Oncol. 2019 Apr 10;37(11):867-875. (PMID: 30811280) J Immunother Cancer. 2019 Nov 21;7(1):316. (PMID: 31752994) Arch Ophthalmol. 2008 Oct;126(10):1413-8. (PMID: 18852420) Acta Ophthalmol. 2018 Jun;96(4):331-347. (PMID: 29105334) Ann Oncol. 2019 Aug 1;30(8):1370-1380. (PMID: 31150059) J Immunother Cancer. 2021 Jan;9(1):. (PMID: 33483342) J Immunother Cancer. 2020 Jun;8(1):. (PMID: 32581057) Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9. (PMID: 14578381) J Clin Oncol. 2020 Nov 20;38(33):3863-3873. (PMID: 32910710) Eur J Cancer. 2019 Sep;119:168-178. (PMID: 31445199) Radiology. 2019 Oct;293(1):223-231. (PMID: 31453767) J Clin Oncol. 2002 Jan 1;20(1):289-96. (PMID: 11773181) J Immunother Cancer. 2019 Nov 13;7(1):299. (PMID: 31722735) Lancet Oncol. 2017 Jun;18(6):792-802. (PMID: 28395880) J Urol. 2003 Nov;170(5):1742-6. (PMID: 14532767) |
| فهرسة مساهمة: | Keywords: CTLA4; PD1; immune checkpoint inhibitor; immunotherapy; predictive score; prognostic; uveal melanoma |
| تواريخ الأحداث: | Date Created: 20210724 Latest Revision: 20210729 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8306971 |
| DOI: | 10.3390/cancers13143640 |
| PMID: | 34298857 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder كن أول من يترك تعليقا!